Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.85), $0.01 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $18.31 million versus the consensus estimate of $16.17 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.